Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 4:34 AM ET

Biotechnology

Company Overview of Synageva BioPharma Corp.

Company Overview

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL) under the Kanuma brand name for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy in a Phase 1/2 study for lysosomal storage disease, known as mucopolysaccharidosis type IIIB; SBC-105, an enzyme replacement therapy in preclinical...

33 Hayden Avenue

Lexington, MA 02421

United States

Founded in 1996

282 Employees

Phone:

781-357-9900

Fax:

781-357-9901

Key Executives for Synageva BioPharma Corp.

Chief Executive Officer, President and Secretary
Age: 45
Chief Financial Officer and Senior Vice President
Age: 48
Chief Operating Officer
Age: 47
Chief Medical Officer, Head of Research & Development and Executive Vice President
Age: 53
Chief Legal Officer, Senior Vice President and General Counsel
Compensation as of Fiscal Year 2015.

Synageva BioPharma Corp. Key Developments

Synageva Biopharma Corp. Announces Resignation of Directors

Alexion Pharmaceuticals Inc. announced acquisition of Synageva BioPharma Corp. In connection with the first merger and as contemplated by the merger agreement, Michael V. Greco, became the sole director of the company. In connection therewith, each of Felix J. Baker, Stephen R. Biggar, Stephen R. Davis, Thomas R. Malley, Sanj K. Patel, Barry D. Quart, Thomas J. Tisch and Peter Wirth tendered their respective resignations as directors from the board of directors of the company and from all committees of the Board on which such directors served, effective as of the effective time.

Synageva BioPharma Corp.(NasdaqGS:GEVA) dropped from NASDAQ Composite Index

Synageva BioPharma Corp. will be removed from Nasdaq Composite Index.

Synageva BioPharma Corp.(NasdaqGS:GEVA) dropped from NASDAQ Biotechnology Index

Synageva BioPharma Corp. will be removed from NASDAQ Biotech Index.

Similar Private Companies By Industry

Company Name Region
Caisson Biotech, LLC United States
Rozetta-Cell Life Sciences, Inc. United States
Viragen International, Inc. United States
Adjuvance Technologies, Inc. United States
Solaris Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 6, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Synageva BioPharma Corp., please visit www.synageva.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.